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Abstract. There is no broadly effective vaccine available for Neisseria meningitidis serotype B (MenB) since the capsular polysaccharide, 
on which vaccines against the other pathogenic serotypes are based, is structurally identical to human fetal brain-cell adhesion molecules. 
Thus, immune tolerance renders the MenB capsule poorly immunogenic, and the fear of generating autoimmunity hampers its use in a vac-
cine1.
State of the art. The current efforts are focused on surface-exposed protein antigens and a new strategy called Reverse Vaccinology (RV) has 
allowed the identification of novel candidates. The present review hypothesizes that the optimization of those candidates by protein engineering 
may lead to the first universal vaccine against meningitis B2.
The main approach is a multicomponent vaccine (5CMV)  which includes 5 protein antigens identified by RV and selected based on bacteri-
cidal assays (Table1). Though, as none of them elicited an antibody response strong enough when individually tested, they were formulated 
as three recombinant proteins with the aim of inducing better and broader protection: GNA1870 was fused with GNA2091, and GNA2132 
was fused with GNA1030, using a 20 Glycines linker in both cases (fig1A). GNA1994 was included alone in the vaccine, as it’s an homotrimer 
that loses the quaternary structure when combined with others, and its membrane-anchor domain was deleted (∆351-403) (fig1B). An Ou-
ter Membrane Vesicle (OMV) of the bacterium was also added in the vaccine, after demonstrating a 10 fold increase in the titer of antibodies 
elicited in its presence (fig1C). 5CMV is currently developed by Novartis, and has overcome Phase III clinical trials with success3 4.
• 5CMV was formulated by combining RV and 
protein engineering (fig2).
• The same procedure could be applicable to other 
vaccines with similar limitations: high variability 
and low distribution of the antigens. 
• The limits of the strategy are still unknown, but 
it opens “The Structural Vaccinology Era”, where 
the eradication of diseases that have challenged 
the scientific community for years could cease to 
be a utopia5.
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fig1. A possible structure of the components included 
in the 5CMV was proposed, as it is not present in any 
database. It required a previous homology modeling of 
GNA1994 and GNA1030, due to the fact that their struc-
tures have not been solved yet. Both GNA1030 model 
and the fusions shown from two different sights (a-d) 
were built using the Modeller program6, and a possible 
structure of a GNA1994 monomer was obtained from 
iTasser server7(e), as any good template for Modeller 
program was found. The known domains of GNA1994 
and an example of OMV8 are shown (f,g). The quali-
ty of the images was improved using informatics8.
fig2. Suggested strategy for novel vaccines design if the patho-
gen genome and the antigenic structures are known. 
(A) RV is a computer-based procedure which, starting from the 
meningococcal genome, identifies novel antigens following crite-
ria of (1) minimum variability, (2) surface exposed localization 
and (3) broadly distribution between the population4. (B) Rational 
protein designs based on the structure are able to optimize the 
identified antigens.
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REVERSE VACCINOLOGY
PROTEIN ENGINEERING
Site-directed mutagenesis
Epitopes and conserved regions unaltered
Recombinant 
expression
Genome sequenced
Bioinformatics prediction:
Potential candidates identification  
Immunogenicity test:
FACS, ELISA, BSA  
Structure knowledge
Rational design Screening
table1. Characteristics of the five antigens included 
in 5CMV, which were called as GNA (Genome Neis-
seria Antigen) plus a digit.
1
2
6
7
Strengths and weaknessAntigen names
The immunogenicity source is unknown, 
but induces bactericidal antibodies in 
combination with the rest
Only elicits protective antibodies when 
high expressed and in cooperation with   
antibodies induced by fHbp
Highly immunogenic, but only present 
in 50-75% of the isolated strains
Highly immunogenic but extremely va-
riable, without crossed protection
Neisseria adhesin A
(NadA o GNA1994)
Putative periplasmic 
protein
(GNA1030)
Neisseria Heparin 
Binding Antigen
(NHBA o GNA2132)
Neisseria surface     
protein 
(NspA o GNA2091)
Factor H 
binding protein 
(fHbp o GNA1870)
Highly conserved, but not immunoge-
nic in the native form because of poor      
epitope exposition
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